SAR of non-hydrolysable analogs of pyridoxal 5′-phosphate against low molecular weight protein tyrosine phosphatase isoforms
作者:Shirin R. DeSouza、Maxwell C. Olson、Samantha L. Tinucci、Erica K. Sinner、Rebecca S. Flynn、Quinlen F. Marshall、Henry V. Jakubowski、Edward J. McIntee
DOI:10.1016/j.bmcl.2020.127342
日期:2020.8
a role in these diseases. Pyridoxal 5′-phosphate (PLP) has been shown to act as a potent but, impractical micromolar inhibitor for both isoforms. In this study, a series of non-hydrolysable phosphonate analogs of PLP were designed, synthesized and tested against the two isoforms of LMW-PTP. Assay results demonstrated that the best inhibitor for both isoforms was compound 5 with a Kis of 1.84 μM (IFA)
激酶和磷酸酶是细胞信号转导途径中的关键酶。这些酶的失衡与多种疾病有关,从癌症到糖尿病再到自身免疫性疾病。低分子量蛋白酪氨酸磷酸酶(LMW-PTP)的两种同工型(IFA和IFB)似乎在这些疾病中起作用。吡醛5'-磷酸酯(PLP)已显示出对两种同工型均有效但不切实际的微摩尔抑制剂。在这项研究中,针对LMW-PTP的两种同工型设计,合成并测试了一系列PLP的不可水解膦酸酯类似物。分析结果表明,两种同工型的最佳抑制剂是化合物5,K分别为1.84μM(IFA)和15.6μM(IFB)。选择性最高的抑制剂是化合物在图16中,IFA的选择性比IFB高约370倍。